Zydus Nikkho Farmaceutica Ltda Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: Zydus Nikkho Farmaceutica Ltda Pharmaceutical Import Records from India — 2 Products, $1.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zydus Nikkho Farmaceutica Ltda — Pharmaceutical Importer Profile (2026) | 2 Products, $1.2M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Zydus Nikkho Farmaceutica Ltda?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zydus Lifesciences Limited	$13.9M	685	96.5%
Cadila Healthcare Limited	$496.7K	16	3.5%
Caplin Steriles Limited	$2.1K	1	0.0%

Zydus Nikkho Farmaceutica Ltda sources from 3 verified Indian suppliers across 462 distinct formulations. The sourcing is highly concentrated — Zydus Lifesciences Limited accounts for 96.5% of total imports, indicating a strategic single-source relationship.

What Formulations Does Zydus Nikkho Farmaceutica Ltda Import?

Formulation	Value	Ships
Pharma drugs & medicine-divalproex sodiu	$327.3K	9
Pharma drugs & medicine:divalproex sodiu	$225.1K	7
Pharma drugs & medicine-topiramate	$215.9K	5
Tamsulosin hcl pr TAB 0.4MG 30 sale	$193.4K	9
Pharma drugs & medicine-quetiapine	$150.0K	3
Pharma drugs & medicine:paroxetine	$146.6K	3
Pharmaceuticals medicine for human use-lamotrigine tabs USP 100MG 30's sale brz(lamotrigine) 2x15 qty-103,337.000	$139.4K

What Products Does Zydus Nikkho Farmaceutica Ltda Import?

Top Products by Import Value

1Isosorbide$997.3K 2Amiodarone$200.0K

Zydus Nikkho Farmaceutica Ltda Therapeutic Categories — 1 Specializations

Zydus Nikkho Farmaceutica Ltda imports across 1 therapeutic categories, with Cardiovascular (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Cardiovascular

2 products · 100.0% · $1.2M

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Isosorbide	Cardiovascular	$997.3K	35	2.2%	8
2	Amiodarone	Cardiovascular	$200.0K	4	0.3%	18

Key Metrics

Total Import Value$1.2M

Products2

Shipments39

Categories1

CountryBrazil

#1 Rankings0

Indian Suppliers3

Formulations462

Top Categories

Cardiovascular100.0%

Indian Suppliers

Last updated: March 28, 2026

Zydus Nikkho Farmaceutica Ltda — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Zydus Nikkho Farmaceutica Ltda is a Brazilian pharmaceutical company specializing in the wholesale distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on June 27, 2008, in Rio de Janeiro, the company operates as a limited liability entity under the CNPJ number 05.254.971/0006-96. (cnpj.biz) It is a subsidiary of the multinational Zydus Group, which originated in India. The company began its journey in Brazil in 2004 and achieved a significant milestone in 2007 through the acquisition of Nikkho do Brasil, enhancing its portfolio with prescription products and generic drugs.

Zydus Nikkho Farmaceutica Ltda plays a pivotal role in Brazil's pharmaceutical distribution network by importing and distributing a diverse range of pharmaceutical products. Its operations are integral to ensuring the availability of essential medications across the country, thereby contributing to the healthcare sector's efficiency and effectiveness.

2Distribution Network

The company maintains a robust distribution network with multiple facilities across Brazil. Its primary operations are based in Rio de Janeiro, with additional facilities in São Paulo and Espírito Santo. These locations enable Zydus Nikkho Farmaceutica Ltda to effectively manage logistics and ensure timely delivery of pharmaceutical products throughout the country. The strategic positioning of these facilities facilitates efficient distribution and supports the company's commitment to meeting the healthcare needs of the Brazilian population.

Supplier Relationship Intelligence — Zydus Nikkho Farmaceutica Ltda

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The company's sourcing strategy exhibits a high degree of concentration, with a significant reliance on a limited number of suppliers. Notably, Zydus Nikkho Farmaceutica Ltda imports the majority of its pharmaceutical products from Zydus Lifesciences Limited, accounting for approximately 96.5% of its total imports. This concentration suggests a strategic partnership aimed at ensuring consistent product quality and supply reliability. However, such dependency also poses potential risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges within the supplier's facilities. The company's limited diversification in sourcing could impact its ability to mitigate these risks effectively.

2Supply Chain Resilience

Zydus Nikkho Farmaceutica Ltda's supply chain resilience is closely tied to the stability and reliability of its primary supplier, Zydus Lifesciences Limited. The company's limited diversification in sourcing indicates a potential vulnerability to disruptions affecting this supplier. To enhance supply chain resilience, it would be prudent for the company to consider diversifying its supplier base and establishing relationships with additional manufacturers. This strategy would mitigate risks associated with over-reliance on a single supplier and ensure a more robust and adaptable supply chain capable of maintaining consistent product availability in the Brazilian market.

3Strategic Implications

The current sourcing pattern of Zydus Nikkho Farmaceutica Ltda, characterized by a heavy reliance on Zydus Lifesciences Limited, positions the company to benefit from strong supplier relationships and potential cost efficiencies. However, this concentration also exposes the company to risks associated with supply chain disruptions. For Indian exporters, this presents an opportunity to engage with Zydus Nikkho Farmaceutica Ltda by offering alternative products or formulations that complement the existing portfolio. By providing additional options, exporters can help the company diversify its sourcing strategy, thereby enhancing its supply chain resilience and reducing dependency on a single supplier.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the National Health Surveillance Agency (ANVISA) is the primary regulatory authority overseeing the pharmaceutical sector. ANVISA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the Brazilian market. The agency enforces regulations that govern the importation, registration, and commercialization of pharmaceutical products, ensuring compliance with national health standards. Key legislation includes the Health Surveillance Law (Law No. 9,782/1999), which established ANVISA, and the Brazilian Health Regulatory Framework, which outlines the procedures for drug approval and market authorization.

2Import Licensing & GMP

Import licensing in Brazil requires pharmaceutical companies to obtain authorization from ANVISA before bringing products into the country. This process involves submitting detailed documentation, including product information, manufacturing processes, and quality control measures. Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards recognized by ANVISA. ANVISA accepts GMP certifications from reputable international bodies, such as the European Medicines Agency (EMA), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications ensure that manufacturing processes meet international quality standards, thereby safeguarding public health.

3Quality & Labeling

Pharmaceutical products imported into Brazil are subject to stringent quality control measures. Batch testing is mandatory to verify the safety, efficacy, and quality of each product batch. Stability studies are required to determine the product's shelf life and ensure its effectiveness over time. Labeling must be in Portuguese and include comprehensive information, such as the product's name, active ingredients, dosage form, usage instructions, and storage conditions. Serialization mandates are enforced to enhance traceability and prevent counterfeit products from entering the market, thereby ensuring consumer safety.

4Recent Regulatory Changes

Between 2024 and 2026, Brazil implemented several regulatory changes affecting pharmaceutical imports. ANVISA introduced more stringent requirements for GMP certification, now mandating that all imported pharmaceutical products possess certifications from PIC/S-recognized authorities. Additionally, the agency updated labeling regulations to include QR codes linking to detailed product information and safety data. These changes aim to enhance transparency, improve consumer access to information, and strengthen the integrity of the pharmaceutical supply chain.

TransData Nexus Research · Brazil regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Zydus Nikkho Farmaceutica Ltda identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Zydus Nikkho Farmaceutica Ltda's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 39 individual customs records matching Zydus Nikkho Farmaceutica Ltda.
5.Supplier Verification: Zydus Nikkho Farmaceutica Ltda sources from 3 verified Indian suppliers across 462 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Zydus Nikkho Farmaceutica Ltda

Zydus Nikkho Farmaceutica Ltda — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Zydus Nikkho Farmaceutica Ltda?

What Formulations Does Zydus Nikkho Farmaceutica Ltda Import?

What Products Does Zydus Nikkho Farmaceutica Ltda Import?

Top Products by Import Value

Zydus Nikkho Farmaceutica Ltda Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Indian Suppliers

Zydus Nikkho Farmaceutica Ltda — Corporate Profile & Information

1Company Overview

2Distribution Network

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Zydus Nikkho Farmaceutica Ltda

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Brazil — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Zydus Nikkho Farmaceutica Ltda — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Zydus Nikkho Farmaceutica Ltda

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Zydus Nikkho Farmaceutica Ltda

What products does Zydus Nikkho Farmaceutica Ltda import from India?

Who supplies pharmaceuticals to Zydus Nikkho Farmaceutica Ltda from India?

What is Zydus Nikkho Farmaceutica Ltda's total pharmaceutical import value?

What therapeutic categories does Zydus Nikkho Farmaceutica Ltda focus on?

Get Full Zydus Nikkho Farmaceutica Ltda Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology